Ngoc Ly, MD, MPH

Ngoc P. Ly, MD, MPH is Professor of Pediatrics, Division Chief of Pediatric Pulmonology, Director of the Cystic Fibrosis Therapeutic Development Network (TDN) Research Center, co-Director of the Cystic Fibrosis Center, and Director of the Asthma Program at the University of California, San Francisco.

Ly is a pediatric pulmonologist with clinical and research interests in asthma, cystic fibrosis (CF), exercise testing and bronchopulmonary dysplasia (BDP). She is a lead investigator on several cystic fibrosis and asthma clinical research projects and trials, including those funded by Cystic Fibrosis Foundation (CFF) and TDN, National Science Foundation (NSF) and National Institute of Health (NIH).

Ly is the program director of the HRSA Maternal and Child Health Pediatric Pulmonary Center (PPC) at UCSF. The purpose of the PPC is to improve the health status of infants, children, and adolescents with chronic respiratory conditions, sleep issues, and other related special health care needs through graduate and post-graduate level interdisciplinary training of health professionals and through working within collaborative systems that promote family-centered care, public health practices, and cultural competence to address health disparities and expand access to care.

Ly is devoted to mentoring students, residents, fellows, and junior faculty.
01/2021 - Diversity, Equity, and Inclusion Champion Training, University of California, San Francisco
Respiratory and Environmental Epidemiology, 2006 - Channing Laboratory, Brigham & Women's Hospital and Harvard School of Medicine
MPH, 2004 - Public Health, Harvard School of Public Health
Pediatric Pulmonary Fellowship, 2004 - Pediatrics, Massachusetts General Hospital and Harvard Medical School
Pediatric Residency, 2001 - Pediatrics, Medical College of Virginia
M.D., 1998 - School of Medicine, University of Rochester
Honors and Awards
  • Exceptional Physician Award, UCSF, 2017
  • Faculty Mentorship Award, Fellows Leadership Advocacy Group (FLAG), UCSF, 2014
  1. Food insecurity and mental health during the COVID-19 pandemic in cystic fibrosis households.
  2. Patient and Provider Experience With Cystic Fibrosis Telemedicine Clinic.
  3. 548: Evaluation of elexacaftor/tezacaftor/ivacaftor on pulmonary function in cystic fibrosis patients.
  4. The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years.
  5. PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.
  6. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States.
  7. Outcomes of Children With Cystic Fibrosis Admitted to PICUs.
  8. The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.
  9. Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models.
  10. Severe Asthma: Clinical Studies and Clinical Trials in Children.
  11. Severe asthma during childhood and adolescence: A longitudinal study.
  12. Development and initial validation of the Asthma Severity Scoring System (ASSESS).
  13. Clinical significance of the bronchodilator response in children with severe asthma.
  14. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States.
  15. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.
  16. Challenges in assessing the efficacy of systemic corticosteroids for severe wheezing episodes in preschool children.
  17. Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
  18. Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma.
  19. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.
  20. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations.
  21. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.
  22. Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.
  23. Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma.
  25. A 6-Month-Old Infant With Different Capnography Values in Polysomnography.
  26. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.
  27. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
  28. Severe Postictal Hypoxemia-Associated Seizure in a 12-Year-Old Child.
  29. Individualized therapy for persistent asthma in young children.
  30. Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.
  31. A 16-Year-Old Boy with Refractory Epilepsy and Sleep-Disordered Breathing.
  32. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial.
  33. Asthma, FEF25–75, and Hospitalizations in Children.
  34. Management of plastic bronchitis with topical tissue-type plasminogen activator.
  35. Maternal intestinal flora and wheeze in early childhood.
  36. Longitudinal relationship of early life immunomodulatory T cell phenotype and function to development of allergic sensitization in an urban cohort.
  37. Reply.
  38. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity?
  39. Race and asthma control in the pediatric population of Hawaii.
  40. Characterization of regulatory T cells in urban newborns.
  41. Title: Relation Of Early Life Regulatory T-cell Function And Phenotype Development To Wheeze And Allergy: The Urban Environment And Childhood Asthma.
  42. Dust mite exposure modifies the effect of functional IL10 polymorphisms on allergy and asthma exacerbations.
  43. Paternal asthma, mold exposure, and increased airway responsiveness among children with asthma in Costa Rica.
  44. Family history, environmental exposures in early life, and childhood asthma.
  45. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood.
  46. Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica.
  47. Cord blood cytokines and acute lower respiratory illnesses in the first year of life.
  48. Maternal antioxidant intake in pregnancy and wheezing illnesses in children at 2 y of age.
  49. Mode of delivery and cord blood cytokines: a birth cohort study.
  50. Recurrent wheeze in early childhood and asthma among children at risk for atopy.
  51. Associations of cord blood fatty acids with lymphocyte proliferation, IL-13, and IFN-gamma.
  52. Netrin-1 inhibits leukocyte migration in vitro and in vivo.
  53. Elevated allergen-induced IL-13 secretion predicts IgE elevation in children ages 2-5 years.
  54. The protease inhibitor PI*S allele and COPD: a meta-analysis.
  55. Cytokines, allergy, and asthma.
  56. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.
  57. Allergen-induced cytokine production, atopic disease, IgE, and wheeze in children.